ADD-ONS / MEDICATION
Lumbar puncture and antithrombotic therapy
Updated on 08/12/2023, published on 07/02/2022
- lumbar puncture (LP), also known as a spinal tap, is an important and commonly performed invasive procedure for obtaining cerebrospinal fluid (CSF) for diagnostic purposes
- the procedure carries some risk of spinal bleeding (most often in the form of an epidural hematoma)
- high-risk conditions include:
- coagulopathies (including pharmacologically induced)
- advanced age
- multiple puncture attempts
- existing spinal pathology
- the potential benefit of the procedure must outweigh the risk of bleeding
- avoid repeated puncture attempts in high-risk patients
- spinal hematoma should be suspected if sudden sensorimotor and/or sphincter deficits or severe low back pain occur after puncture ⇒ perform MRI immediately and consult a neurosurgeon ( after > 8h, the prognosis is already unfavorable despite successful surgery!) [Herlocker, 2010]
- on the other hand, periprocedural discontinuation of antithrombotic medication increases thromboembolism risk
- aspirin withdrawal precedes up to 10.2% of acute cardiovascular syndromes (Burger, 2005)
- the potential benefit of lumbar puncture must always outweigh the risk of thrombosis
- bridging therapy may be necessary in high-risk patients
- consultation with the specialist who prescribed the antithrombotic therapy and a hematologist is recommended
Coagulopathies |
Antiplatelet therapy |
Urgent reversal of antiplatelet drugs effect
- prophylactic reversal of antiplatelet therapy is not a routine procedure and should generally be avoided due to the risk of thrombosis
- 2-3 units of platelets may be considered to provide functional, circulating platelets; consult a hematologist
- studies have shown mixed results regarding the benefit of this practice; there is no standard dose, and no effect was shown in the PATCH trial
- desmopressin (ddAVP) OCTOSTIM – 0,3 ug/kg +100 mL of NS, infused over 15-30 minutes
- the benefit of using desmopressin before lumbar puncture remains unproven; data are only available for general surgery (where a reduced need for transfusion was reported) (Desborough, 2016)
Anticoagulant therapy and thrombolysis |
LMWH bridging
- warfarin
- consider bridging only in high-risk patients (see table below)
- meta-analyses have not shown a clear benefit of bridging, only an increased risk of bleeding
- BRIDGE trial in Afib patients showed non-inferiority of no therapy vs. LMWH bridging (only a few patients with CHADS2 ≥ 5 were enrolled in this trial; CHA2DS2-VASc score was not used)
- for patients with VTE lasting more than 3 months, a prophylactic dose of LMWH may be selected for bridging and should be discontinued 12 hours before surgery
- LMWH at therapeutic dose in high-risk patients should be started when the INR is < 2 (usually 36h after warfarin discontinuation) and discontinued ≥ 24h before surgery/procedure
- after the procedure, restart LMWH within 12-24h (at a therapeutic dose)
- DOAC
- bridging therapy during DOAC discontinuation is not necessary, given the drug’s half-life and short discontinuation period
High-risk patients ⇒ consider LMWH bridging |
|
DVT (deep vein thrombosis / PE) |
|
Atrial fibrillation |
|
Mechanical valve |